 |
|
|
| |
PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR)
|
| |
| |
Reported by Jules Levin
HepDART, Wailea, HI. Dec 6-10, 2015
Ernest Asante-Appiah, Ira Jacobsen, Peggy Wong, Todd Black, Anita Howe, Janice Wahl, Michael N. Robertson, Bach-Yen Nguyen, Melissa Shaughnessy, Peggy Hwang, Eliav Barr and Daria Hazuda
AASLD: Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)
AASLD: Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - (11/16/15)
|
| |
|
|
|
|
|
